Therapeutic Asset Ratings
748 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Triadeno Vaccine
Epithelial Neoplasm
National Cancer Institute (NCI)
P2
CCC
(53)
Tumor Lysate, Particle Only Vaccine
Metastatic Neoplasm
Elios Therapeutics, LLC
P2
CCC
(53)
Tumor Lysate, Particle Only Vaccine
Neoplasm
Elios Therapeutics, LLC
P2
CCC
(53)
uv1
Neoplasm
Vestre Viken Hospital Trust
P2
CCC
(53)
Wokvac Vaccine
Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
P2
CCC
(53)
Wokvac Vaccine
Male Breast Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
P2
CCC
(53)
Wokvac Vaccine
Breast Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
P2
CCC
(53)
Wokvac Vaccine
Residual Disease
H. Lee Moffitt Cancer Center and Research Institute
P2
CCC
(53)
Ino-9012
Hepatocellular Carcinoma
Geneos Therapeutics
P1/2
CCC
(53)
ADAGLOXAD SIMOLENIN
Triple-Negative Breast Carcinoma
OBI Pharma, Inc
P3
CCC
(52)
Moderna Bivalent Mrna Vaccine
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Monash University
P3
CCC
(52)
pcv21
Sickle Cell Disease
Sanofi
P3
CCC
(52)
Pfizer Bivalent Covid-19 Vaccine
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Monash University
P3
CCC
(52)
Prevnar 20
Sickle Cell Disease
Sanofi
P3
CCC
(52)
Multi-Peptide Cmv-Modified Vaccinia Ankara Vaccine
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
City of Hope Medical Center
P2
CCC
(52)
Multi-Peptide Cmv-Modified Vaccinia Ankara Vaccine
Hodgkins Lymphoma
City of Hope Medical Center
P2
CCC
(52)
Neoantigen Dendritic Cell Vaccine
Hepatocellular Carcinoma
National Cancer Centre, Singapore
P2
CCC
(52)
Pneumococcal Polyvalent Vaccine
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Seema Bhat
P2
CCC
(52)
Allostim®
Hepatocellular Carcinoma
Mirror Biologics, Inc.
P2/3
CCC
(52)
ad5 cea vaccine
Colorectal Carcinoma
National Cancer Institute (NCI)
P2
CCC
(51)
Adenovirus 5 Cea/Muc1/Brachyury Vaccine Tri-Ad5
Colorectal Carcinoma
National Cancer Institute (NCI)
P2
CCC
(51)
Adenovirus 5/F35-Human Guanylyl Cyclase C-Padre
Colorectal Adenocarcinoma
Thomas Jefferson University
P2
CCC
(51)
Adenovirus 5/F35-Human Guanylyl Cyclase C-Padre
Gastric Adenocarcinoma
Thomas Jefferson University
P2
CCC
(51)
Dpx-Survivac
Cancer
University Health Network, Toronto
P2
CCC
(51)
Dpx-Survivac
Urinary Bladder Carcinoma
ImmunoVaccine Technologies, Inc. (IMV Inc.)
P2
CCC
(51)
Showing 301 to 325 of 748 assets
Previous
Page 13 of 30
Next